Evaluation of off-label rapamycin use to promote healthspan in 333 adults

Geroscience. 2023 Oct;45(5):2757-2768. doi: 10.1007/s11357-023-00818-1. Epub 2023 May 16.

Abstract

Rapamycin (sirolimus) is an FDA-approved drug with immune-modulating and growth-inhibitory properties. Preclinical studies have shown that rapamycin extends lifespan and healthspan metrics in yeast, invertebrates, and rodents. Several physicians are now prescribing rapamycin off-label as a preventative therapy to maintain healthspan. Thus far, however, there is limited data available on side effects or efficacy associated with use of rapamycin in this context. To begin to address this gap in knowledge, we collected data from 333 adults with a history of off-label use of rapamycin by survey. Similar data were also collected from 172 adults who had never used rapamycin. Here, we describe the general characteristics of a patient cohort using off-label rapamycin and present initial evidence that rapamycin can be used safely in adults of normal health status.

Keywords: Aging; COVID-19; Healthspan; Longevity; Rapamune; SARS-CoV-2; Side effects; Sirolimus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Longevity
  • Off-Label Use*
  • Sirolimus* / pharmacology
  • TOR Serine-Threonine Kinases

Substances

  • Sirolimus
  • TOR Serine-Threonine Kinases